Westwood

Futó vizsgálatok

• Még nem toboroz

  LTFU for All Cell and Gene Therapy Studies

  NCT06194461· Forrás

• Toboroz

  Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  NCT06218914· 1. fázis· Forrás

• Toboroz

  Study of AZD0754 in Participants With Metastatic Prostate Cancer

  NCT06267729· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma

  NCT06084884· 1/2. fázis· Forrás

• Fut, nem toboroz

  Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents

  NCT06120491· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03)

  NCT05629585· 3. fázis· Forrás

• Fut, nem toboroz

  Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

  NCT04590963· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

  NCT04305496· 3. fázis· Forrás

• Fut, nem toboroz

  Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

  NCT03997123· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)

  NCT03875235· 3. fázis· Forrás

• Fut, nem toboroz

  Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

  NCT03732677· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

  NCT03298451· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

  NCT02972840· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Prosztatarák2 toboroz
• Hasnyálmirigyrák1 toboroz
• Máj- és epeúti rák1 toboroz
• Méhtestrák1 toboroz
• Tüdőrák1 toboroz
• Vastagbélrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

  NCT04686305· 1. fázis· Forrás

• Lezárult

  Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment

  NCT03847428· 3. fázis· Forrás